Observational studyNeurology2018
Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
Observational study in Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Acute Sensory and Autonomic Neuronopathy: A Devastating Disorder Affecting Sensory and Autonomic Ganglia.Seminars in neurology · 2020Pooled it
- Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2021Trial
- Cardiovascular autonomic failure correlates with cutaneous autonomic denervation in PD and MSA.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026Article
- Hypertensive emergency with vasogenic cerebral edema following droxidopa initiation in pure autonomic failure.Frontiers in neurology · 2026Article
- Approach to Cardiovascular Autonomic Dysfunction in Patients with Synucleinopathies.Movement disorders clinical practice · 2025Review
- Neurogenic Orthostatic Hypotension in Parkinson Disease-A Narrative Review of Diagnosis and Management.Journal of clinical medicine · 2025Review
- Article
- Effects of Atomoxetine for the Treatment of Neurogenic Orthostatic Hypotension in Patients With Alpha-synucleinopathies: A Systematic Review of Randomized Controlled Trials and a Focus-Group Discussion.Journal of clinical neurology (Seoul, Korea) · 2023Article
- Updates on the Diagnosis and Treatment of Peripheral Autonomic Neuropathies.Current neurology and neuroscience reports · 2022Review
- Orthostatic Hypotension in Parkinson Disease: What Is New?Neurology. Clinical practice · 2022Article
- Management of Orthostatic Hypotension in the Hospitalized Patient: A Narrative Review.The American journal of medicine · 2022Review
- Predictors of the Pressor Response to the Norepinephrine Transporter Inhibitor, Atomoxetine, in Neurogenic Orthostatic Hypotension.Hypertension (Dallas, Tex. : 1979) · 2021Article
- Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2021Article
- Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2021Article
- Management Strategies for Comorbid Supine Hypertension in Patients with Neurogenic Orthostatic Hypotension.Current neurology and neuroscience reports · 2021Review
- Spectrum of diabetic neuropathies.Diabetology international · 2020Review
- Management of Orthostatic Hypotension.Continuum (Minneapolis, Minn.) · 2020Review
- Orthostatic Hypotension in Parkinson Disease.Clinics in geriatric medicine · 2020Review
- Management of Orthostatic Hypotension in Parkinson's Disease.Journal of Parkinson's disease · 2020Review
- Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer.Neurology and therapy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo test whether the plasma levels of norepinephrine (NE) in patients with neurogenic orthostatic hypotension (nOH) predict their pressor response to droxidopa.
methodsThis was an observational study, which included patients with nOH. All patients had standardized autonomic function testing including determination of venous plasma catecholamine levels drawn through an indwelling catheter while resting supine. This was followed by a droxidopa titration with 100 mg increments in successive days until relief of symptoms, side effects, or the maximum dose of 600 mg was reached. No response was defined as an increase of <10 mm Hg in systolic blood pressure (BP) after 3-minute standing 1 hour after droxidopa administration. Nonlinear regression models were used to determine the relationship between BP response and plasma NE levels.
resultsWe studied 20 patients with nOH due to Parkinson disease, pure autonomic failure, multiple system atrophy, or autoimmune autonomic neuropathies. Their supine plasma NE levels ranged from 44 to 850 pg/mL. Lower supine plasma NE levels were associated with greater pressor effect 1 hour after dose (R
conclusionsIn patients with nOH, lower supine resting plasma NE levels are associated with a greater pressor effect of droxidopa treatment. This finding should help identify patients with nOH most likely to respond to standard doses of droxidopa. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that lower supine plasma NE levels accurately identify patients with nOH more likely to have a greater pressor effect from droxidopa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.